These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 20299272)
1. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Goetz C; Gromeier M Cytokine Growth Factor Rev; 2010; 21(2-3):197-203. PubMed ID: 20299272 [TBL] [Abstract][Full Text] [Related]
2. Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. Cello J; Toyoda H; Dejesus N; Dobrikova EY; Gromeier M; Wimmer E J Med Virol; 2008 Feb; 80(2):352-9. PubMed ID: 18098139 [TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Ochiai H; Campbell SA; Archer GE; Chewning TA; Dragunsky E; Ivanov A; Gromeier M; Sampson JH Clin Cancer Res; 2006 Feb; 12(4):1349-54. PubMed ID: 16489093 [TBL] [Abstract][Full Text] [Related]
4. A host-specific, temperature-sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO). Jahan N; Wimmer E; Mueller S J Virol; 2011 Jul; 85(14):7225-35. PubMed ID: 21561914 [TBL] [Abstract][Full Text] [Related]
5. Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. Dobrikova EY; Goetz C; Walters RW; Lawson SK; Peggins JO; Muszynski K; Ruppel S; Poole K; Giardina SL; Vela EM; Estep JE; Gromeier M J Virol; 2012 Mar; 86(5):2750-9. PubMed ID: 22171271 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. Yang X; Chen E; Jiang H; Muszynski K; Harris RD; Giardina SL; Gromeier M; Mitra G; Soman G J Virol Methods; 2009 Jan; 155(1):44-54. PubMed ID: 18951922 [TBL] [Abstract][Full Text] [Related]
7. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Brown MC; Gromeier M Curr Opin Virol; 2015 Aug; 13():81-5. PubMed ID: 26083317 [TBL] [Abstract][Full Text] [Related]
8. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. Walton RW; Brown MC; Sacco MT; Gromeier M J Virol; 2018 Oct; 92(19):. PubMed ID: 29997212 [TBL] [Abstract][Full Text] [Related]
9. Polypyrimidine tract binding protein-1 (PTB1) is a determinant of the tissue and host tropism of a human rhinovirus/poliovirus chimera PV1(RIPO). Jahan N; Wimmer E; Mueller S PLoS One; 2013; 8(4):e60791. PubMed ID: 23593313 [TBL] [Abstract][Full Text] [Related]
10. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Dobrikova EY; Broadt T; Poiley-Nelson J; Yang X; Soman G; Giardina S; Harris R; Gromeier M Mol Ther; 2008 Nov; 16(11):1865-72. PubMed ID: 18766173 [TBL] [Abstract][Full Text] [Related]
11. Recombinant Poliovirus for Cancer Immunotherapy. Gromeier M; Nair SK Annu Rev Med; 2018 Jan; 69():289-299. PubMed ID: 29414253 [TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. Campbell SA; Lin J; Dobrikova EY; Gromeier M J Virol; 2005 May; 79(10):6281-90. PubMed ID: 15858012 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Toyoda H; Yin J; Mueller S; Wimmer E; Cello J Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Wollmann G; Ozduman K; van den Pol AN Cancer J; 2012; 18(1):69-81. PubMed ID: 22290260 [TBL] [Abstract][Full Text] [Related]
15. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses. Durupt F; Koppers-Lalic D; Balme B; Budel L; Terrier O; Lina B; Thomas L; Hoeben RC; Rosa-Calatrava M Cancer Gene Ther; 2012 Jan; 19(1):58-68. PubMed ID: 22015640 [TBL] [Abstract][Full Text] [Related]
16. Sensitivity of C6 Glioma Cells Carrying the Human Poliovirus Receptor to Oncolytic Polioviruses. Sosnovtseva AO; Lipatova AV; Grinenko NF; Baklaushev VP; Chumakov PM; Chekhonin VP Bull Exp Biol Med; 2016 Oct; 161(6):821-825. PubMed ID: 27783287 [TBL] [Abstract][Full Text] [Related]
17. MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Goetz C; Everson RG; Zhang LC; Gromeier M Mol Ther; 2010 Nov; 18(11):1937-46. PubMed ID: 20648000 [TBL] [Abstract][Full Text] [Related]
18. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus. Ramachandran M; Yu D; Dyczynski M; Baskaran S; Zhang L; Lulla A; Lulla V; Saul S; Nelander S; Dimberg A; Merits A; Leja-Jarblad J; Essand M Clin Cancer Res; 2017 Mar; 23(6):1519-1530. PubMed ID: 27637889 [No Abstract] [Full Text] [Related]
19. Therapeutic Use of Native and Recombinant Enteroviruses. Ylä-Pelto J; Tripathi L; Susi P Viruses; 2016 Feb; 8(3):57. PubMed ID: 26907330 [TBL] [Abstract][Full Text] [Related]
20. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. Merrill MK; Gromeier M J Virol; 2006 Jul; 80(14):6936-42. PubMed ID: 16809299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]